Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
| العنوان: | Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial |
|---|---|
| المؤلفون: | Ewan R. Pearson, Jagdeep Singh, Anna Maria Choy, Stephen J. Gandy, J. Graeme Houston, Ify R. Mordi, Amir Fathi, Mohapradeep Mohan, Jacob George, Keeran Vickneson, Faisel Khan, Peter T. Donnan, Allan D. Struthers, Chim C. Lang |
| المصدر: | Diabetes Care |
| بيانات النشر: | American Diabetes Association, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, medicine.drug_class, Heart Ventricles, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Hematocrit, Placebo, Cohort Studies, Placebos, Ventricular Dysfunction, Left, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Glucosides, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Benzhydryl Compounds, Dapagliflozin, Ventricular remodeling, Aged, Heart Failure, Advanced and Specialized Nursing, Ventricular Remodeling, medicine.diagnostic_test, business.industry, Stroke Volume, Middle Aged, Loop diuretic, medicine.disease, Novel Communications in Diabetes, Blood pressure, Diabetes Mellitus, Type 2, chemistry, Heart failure, Cardiology, Female, business, Diabetic Angiopathies |
| الوصف: | OBJECTIVE To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. RESEARCH DESIGN AND METHODS We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters. RESULTS In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight. CONCLUSIONS We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown. |
| تدمد: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc19-2187 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b2e8a2f28e087ec1e615ca5ff4e3ae https://doi.org/10.2337/dc19-2187 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....07b2e8a2f28e087ec1e615ca5ff4e3ae |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|---|
| DOI: | 10.2337/dc19-2187 |